Belgian spin-off Indigo challenges diabe... Indigo Diabetes NV has been spun-off from University of Ghent and international research institute imec with a series A financing of €7m. The company’s needle-free glucose sensor addresses … more ➔
EMA recommends market approval of four b... The Europan Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended four biologics, among them three biosimilars, one monoclonal antibody as well as two targeted … more ➔
Evotec bags US$45m upfront in Celgene dealNeurology specialist Celgene has nailed down access to Evotec’s induced pluripotent stem cell (iPSC) platform for screening of compounds against neurodegenerative diseases. more ➔
Grifols confirms €1.75bn acquisition in...Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit. more ➔
Oncology: Orion teams up with Wi2 Finnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance. more ➔
Curetis bags EIB debt financing and expa... Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive … more ➔
Crenezumab data support Amyloid-beta tar... While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further … more ➔
TxCell gains Treg rightsFrench immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive … more ➔
Researchers report ubiquitous cancer tar...UK researchers have identified a highly conserved target structure that can be directed to rush dividing cancer cells into premature division and cell death. more ➔
Merck expands portfolio of liquid biopsy...Merck KGaA has expanded its portfolio of blood-based RAS diagnostics for use in patient stratification. After kicking off testing with Sysmex Inostics’ CE-marked OncoBEAM RAS CRC liquid biopsy … more ➔
